A New Test for Patient-Reporting of Mastocytosis Control + +++ +++ +++ ++

FEATURED ARTICLE A New Test for Patient-Reporting of Mastocytosis Control https://checkrare.com/a-new-test-for-patient-reporting-of-mastocytosis-control/ A team of allergists, immunologists, and dermatologists sought to test a new patient-reported outcomes measure for assessing mastocytosis disease control. Their newly developed tool, called the Mastocytosis Control Test (MCT), was generated through interviews with adult patients with nonadvanced indolent systemic mastocytosis. CLINICAL PERSPECTIVES ORIGIN 3 Clinical Trial Evaluating Atacicept in Adults With IgA Nephropathy https://checkrare.com/origin-3-clinical-trial-evaluating-atacicept-in-adults-with-iga-nephropathy/ Richard Lafayette, MD, Professor of Medicine at Stanford University, discusses the ORIGIN clinical trial evaluating atacicept in adults with IgA nephropathy (IgAN). The Use of Nipocalimab in Adolescent Patients With Generalized Myasthenia Gravis https://checkrare.com/the-use-of-nipocalimab-in-adolescent-patients-with-generalized-myasthenia-gravis/ Jonathan Strober, MD, pediatric neurologist and neuromuscular specialist at the University of California at San Francisco, discusses the use of nipocalimab in adolescent patients with generalized myasthenia gravis (gMG). EPIC Clinical Trial Design: Evaluating Nipocalimab Versus Efgartigimod in Patients With Myasthenia Gravis https://checkrare.com/epic-clinical-trial-design-evaluating-nipocalimab-versus-efgartigimod-in-patients-with-myasthenia-gravis/ Nolan Campbell, PhD, U.S. Medical Director at Johnson & Johnson, discusses the EPIC clinical trial design that will evaluate the efficacy of nipocalimab versus efgartigimod in patients with generalized myasthenia gravis (gMG). Efficacy of Nipocalimab in Generalized and Ocular gMG: Long-Term Outcomes and Phase 3 VIVACITY-MG3 Findings https://checkrare.com/efficacy-of-nipocalimab-in-generalized-and-ocular-gmg-long-term-outcomes-and-phase-3-vivacity-mg3-findings/ Sindhu Ramchandren, MD, Executive Medical Director of Neuroscience at Johnson & Johnson, discusses long-term efficacy of nipocalimab in patients with generalized myasthenia gravis (gMG). The Shift to Precision Medicine in Myasthenia Gravis https://checkrare.com/the-shift-to-precision-medicine-in-myasthenia-gravis/ Alexandra C. Bayer Wildberger, PhD, Post-Doctoral Associate at Yale School of Medicine, discusses the shift to precision medicine in myasthenia gravis (MG). Long-Term Data From the AQUARIUS Study of Avacopan in Patients With GPA and MPA https://checkrare.com/long-term-data-from-the-aquarius-study-of-avacopan-in-patients-with-gpa-and-mpa/ Naomi Patel, MD, MPH, Rheumatologist at Massachusetts General Hospital, discusses long-term data from the AQUARIUS study of avacopan in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Data on the RAISE Clinical Trial Program of Zilucoplan for the Treatment of Myasthenia Gravis https://checkrare.com/data-on-the-raise-clinical-trial-program-of-zilucoplan-for-the-treatment-of-myasthenia-gravis/ Michael Weiss, MD, Neurologist at the University of Washington, discusses data on the RAISE and RAISE-XT clinical trials of zilucoplan for the treatment of generalized myasthenia gravis (gMG). New Data on Vyvgart for Patients With AChR-Ab Seronegative Myasthenia Gravis https://checkrare.com/new-data-on-vygart-for-patients-with-achr-ab-seronegative-myasthenia-gravis/ James Howard, Jr., MD, Professor of Neurology at the University of North Carolina, discusses new data on the safety and efficacy of Vyvgart (efgartigimod alfa) for patients with AChR-Ab seronegative generalized myasthenia gravis (gMG). A Patient’s Diagnostic Journey With Systemic Mastocytosis https://checkrare.com/a-patients-diagnostic-journey-with-systemic-mastocytosis/ Joan Smith, patient with systemic mastocytosis, discusses her diagnostic journey with systemic mastocytosis (SM).